BIO-11006 is under clinical development by BioMarck Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect BIO-11006’s likelihood of approval (LoA) and phase transition for Chronic Obstructive Pulmonary Disease (COPD) took place on 05 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BIO-11006 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
BIO-11006 is under development for the treatment of chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, non-small cell lung cancer, pediatric solid tumors, pyoderma gangrenosum and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), uveitis, recurrent osteosarcoma, skin inflammation, atopic dermatitis, psoriasis and Ewing's sarcoma. The drug candidate is administered as an aerosolized inhalational solution. The drug candidate is a crystalline, small soluble peptide with ten amino acids. It targets myristoylated alanine-rich C-kinase substrate (MARCKS) protein. It is derived from the N-terminal peptide of MARCKS protein. The drug candidate is based on drug and disease target identification technology.
BioMarck Pharmaceuticals overview
BioMarck Pharmaceuticals (BioMarck ) is a biopharmaceutical company that utilizes anti-MARCKS peptides for developing and licensing products targeted at difficult to treat diseases.
Quick View BIO-11006 LOA Data
|Highest Development Stage|